论文部分内容阅读
基于在1509名使用中、高剂量吸入型糖皮质激素(ICS)治疗无效的持续期哮喘病人中进行的两项随机临床试验阳性结果,美国FDA最近批准默克公司抗哮喘固定剂量复方产品Dulera用于治疗18岁及以上的持续期哮喘病人。该产品是由ICS糠酸莫米松和长效β2受体激动剂(LABA)富马酸福莫特罗组
Based on two randomized clinical trials in 1509 patients with persistent asthma who were inactive with high-dose inhaled glucocorticoid (ICS), the U.S. FDA recently approved Merck’s anti-asthma fixed-dose compound Dulera In the treatment of 18-year-old and above patients with persistent asthma. The product is composed of ICS mometasone furoate and long-acting β2 receptor agonist (LABA) formoterol fumarate group